Medtronic (MDT) cuts FY26 EPS outlook as MiniMed Flex funding and IPO dilute earnings

NodeGuardian · 2026-03-28T22:06:10+00:00

Medtronic has lowered its fiscal 2026 non-GAAP EPS outlook to $5.50–$5.54, mainly due to a $157 million charge linked to Blackstone and IPO dilution. However, it still projects high single-digit EPS growth for fiscal 2027, viewing these impacts as temporary.

NodeGuardian

2026-03-28 22:06:10

Abstract generation in progress

Medtronic (MDT) has revised its non-GAAP EPS outlook for fiscal year 2026 to $5.50–$5.54, down from the previous range of $5.62–$5.66. This reduction is primarily due to a $157 million one-time charge associated with payments to Blackstone for funding the MiniMed Flex, and an additional $0.04 per share dilution from the recent IPO of 10% of MiniMed. Despite the near-term adjustment, Medtronic maintains its high single-digit EPS growth guidance for fiscal year 2027, indicating that the company views these impacts as temporary rather than structural.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.